Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of AC591 granules for prevention of oxaliplatin-induced peripheral neuropathy
CTR20243618Phase 2Active
- Sponsor
- Jiangsu Province Hospital on Integration of Chinese and Western Medicine
- Start
- Feb 2025
- Countries
- 1
01
Overview
A Phase 2 trial of AC591 in chemotherapy-induced peripheral neuropathy (CIPN), peripheral neuropathy, sponsored by Jiangsu Province Hospital on Integration of Chinese and Western Medicine. Started Feb 2025; status: active.
02
Drugs
AC591
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)peripheral neuropathy
Beyond the preview
Go deeper on CTR20243618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243618.